Overall, these results confirm that proglumide treatment alters expression of the FXR-FGFR4 axis in mouse tissues, FGFR4 expression is downregulated in NASH livers, and proglumide restores the expression to normal levels. The gene discussed is FGFR4; the disease is metabolic dysfunction-associated steatohepatitis.